Top 10 Small-Cap Biotechs with Upcoming Catalysts for 2025Here are 10 small cap biotech stocks with notable upcoming catalysts in 2025—ranging from trial readouts and FDA decisions to pivotal data and corporate milestones:
________________________________________
🔬 Top 10 Small-Cap Biotechs with Upcoming Catalysts for 2025
1. Crinetics Pharmaceuticals (NASDAQ: CRNX)
• Catalyst: FDA PDUFA deadline for paltusotine (oral acromegaly treatment) expected by September 25, 2025.
• Focused on endocrine diseases and advancing pipeline beyond acromegaly (en.wikipedia.org).
Stock market information for Crinetics Pharmaceuticals Inc (CRNX)
• Crinetics Pharmaceuticals Inc is a equity in the USA market.
• The price is 32.33 USD currently with a change of -0.73 USD (-0.02%) from previous close.
• The latest open price was 33.1 USD and the intraday volume is 420639.
• The intraday high is 33.34 USD and the intraday low is 32.32 USD.
• The latest trade time is Wednesday, June 11, 23:45:00 +0300.
________________________________________
2. Viking Therapeutics
• Catalyst: Late-stage trial start for injectable weight-loss drug (GLP 1/GIP); mid-stage data readout for oral candidate due in 2025 (barrons.com).
• Strong analyst sentiment: Jefferies forecasts ~223% upside
________________________________________
3. Insmed (NASDAQ: INSM)
• Catalyst: Phase III/inhalable powder treprostinil palmitil for pulmonary arterial hypertension; recent results exceeded expectations; full Phase III data due in 2025
________________________________________
4. Kymera Therapeutics
• Catalyst: Phase I for KT 621 (oral STAT6 degrader for dermatitis/asthma); next-stage readouts expected late 2025–early 2026
• Shares rose ~50% on initial results; further trials underway
________________________________________
5. Arcutis Biotherapeutics (NASDAQ: ARQT)
• Catalyst: Technical breakout potential near $17.75; continued quarterly readouts with rising sales (33% last quarter)
• Upcoming investor calls/publication strategies may accelerate momentum.
________________________________________
6. Rhythm Pharmaceuticals (NASDAQ: RYTM)
• Catalyst: With FDA-approved Imcivree for genetic obesity, further label expansion or mid-to-late-stage trial results anticipated in 2025
• Institutional buying trends and revenue growth support upcoming readouts .
________________________________________
7. BeOne Medicines (Ticker: ONC)
• Catalyst: Early human data in solid tumor oncology; multiple upcoming trials in 2025 .
• Q1 2025 marked first profit; strong institutional support
________________________________________
8. Mesoblast Ltd & Capricor Therapeutics
• Catalyst: Stem-cell therapies targeting GvHD, heart failure, Duchenne muscular dystrophy—key FDA decisions expected in H2 2025
• Maxim Group flags pivotal year for approvals and stock catalysts (marketwatch.com).
________________________________________
9. Acelyrin (NASDAQ: SLRN)
• Catalyst: Phase III results for lonigutamab in thyroid eye disease; shareholder vote on Alumis merger around May 2025
• Merger closing and clinical readouts may drive volatility .
________________________________________
10. ADC Therapeutics & Foghorn Therapeutics & Pyxis Oncology
• Catalysts: Multiple preclinical/early clinical updates presented at AACR (April 2025)
o ADC Therapeutics (ADCT): Readouts on 6 ADC programs (Claudin 6, NaPi2b, etc.).
o Foghorn (FHTX): Preclinical updates on EP300, FHD609, FHD909.
o Pyxis Oncology (PYXS): Phase I ADC and Siglec 15 antibody data.
________________________________________
🔎 How to Monitor These Catalysts
• FDA PDUFA dates (Crinetics, Mesoblast/Capricor, Viking)
• Trial readouts/ASC presentations (Kymera, Insmed, ADC Therapeutics, Foghorn, Pyxis)
• M&A/news events (BeOne, Acelyrin merger)
________________________________________
📊 Summary Table
Ticker Company Upcoming Catalyst Timeframe
CRNX Crinetics PDUFA paltusotine NDA Sep 25, 2025
Viking Viking Therapeutics Injectable Phase III, oral Phase II data From mid-2025
INSM Insmed PAH inhalable Phase III readout Mid-to-late 2025
Kymera Kymera Therapeutics Dermatitis/asthma Phase I → Phase II Late 2025 – 2026
ARQT Arcutis Biotherapeutics Continued quarterly updates Throughout 2025
RYTM Rhythm Pharmaceuticals Label expansion/trial updates 2025
ONC BeOne Medicines Solid tumor trial data 2025
Mesoblast/Capricor Stem-cell stocks FDA decisions H2 2025
SLRN Acelyrin EMA/merger vote + Phase III readout May–Q3 2025
ADCT/FHTX/PYXS AACR presenters Academic readouts on multiple programs April 2025
________________________________________
⚠️ A Word of Caution
Small-cap biotech involves high volatility—catalyst events often drive sharp price swings, both up and down. Thorough due diligence is essential.
ETF market
QQQ - Weekly Volatility PotentialGood Morning --
Last week we reviewed the potential of the S&P 500, this week let us take a look at the potential perspective of NASDAQ:QQQ .
IV (17.97%) entering the week is trending 31% IVp on the year and has been gradually lowering as price action grinds higher and out of corrective territory -- This is +2.61% more volatile than near-term trending values of HV10 (15.36%) and only -0.57% under HV21 (18.54%), our monthly trending values.
Looking towards next week, I expect the CBOE:VIX to continually soften IV values as the broader markets push towards all-time highs this week. NASDAQ:QQQ historical values are coiling to where we will soon need a volatility spike, but not just yet -- my weekly price target here is simple (HV10 upper implied range) $539.44 with wicking potential above to monthly trends (HV21 upper implied ranges) at $541.42.
Only time will tell, we can't control the markets but we sure can manage our own risk within them. Remember to always be hedged and come back to join me next weekend as we review the charts for what happened VS our expectation!
CHEERS
BITx - Weekly Volatility PotentialGood Morning!
Here is my weekly perspective for CBOE:BITX --
From when we reviewed last weekend, IV (84.60%) has lowered -2.39% and is entering the week with a 2% IVp. We have been in this pattern of rotating IV and Bi-Weekly volatility trends back and forth as HV10 (62.69%) entering the week has increased +2.47% from it's respective level entering last week. The prediction of what is to happen is contracting as what is actually happening in the short-term is trending up.
Bi-Weekly and Monthly volatility values after being 100% coiled and both putting in new yearly lows a month ago are starting to unwind as they create distance from those exact lows.
Could long-term trending means be on the horizon with quarterly values? Bi-weekly will eventually find it's way back there, question is when. Our best advantage, is to continue to track the data and ebb and flow with the markets and macro news.
Looking towards this next week, Our HV10 (62.69%) trending values are still contracting under our monthly HV21 (68.45%) trends, but IV (84.60%) although lowering, is reflecting expansion.
There is a premium capture past stated IV if we can find means regression back to HV63 (99.07%), as what is happening will expand past what is predicted to happen. As of now this value is 14.97% and equates to a premium capture $8.24 or $88.24 per lot or contract.
Again, when IV contracts chasing HV10, but it expands to HV63, we look to collect the premium value difference with the move.
Only time will tell, I think we will see another volume push into this week -- Remember to always be hedged and come back to join me next weekend as we review the charts for what happened VS our expectation!
CHEERS
SPY: Expecting Bullish Movement! Here is Why:
The analysis of the SPY chart clearly shows us that the pair is finally about to go up due to the rising pressure from the buyers.
Disclosure: I am part of Trade Nation's Influencer program and receive a monthly fee for using their TradingView charts in my analysis.
❤️ Please, support our work with like & comment! ❤️
SPY (S&P500) - Price Testing Support Trendline - Daily ChartSPY (S&P500 ETF) price has just closed below $600 and is currently under a support trendline.
If price cannot breakout above the $600 and $605 resistance level this month, a pullback could occur down to the support zone.
SPY price could potentially pullback to various levels of support due to:
-USA domestic conflict
-International military conflicts
-Technical chart bearish divergence
-USA federal reserve interest rate news
-Government and corporate news
Support Levels: $595, $590, $585, $580.
Resistance Levels: $600, $605, $610, $615.
The 50EMA/200EMA Golden Cross is still on-going, and support prices of $580 and $568 have yet to be tested significantly.
Israel VS Iran War: Oil Spike!Tensions between Israel and Iran have escalated dramatically, with both nations engaging in direct military strikes. Israel launched Operation Rising Lion, targeting Iran’s nuclear infrastructure, missile factories, and military personnel. In response, Iran retaliated with missile attacks on Israel, hitting Tel Aviv and wounding civilians
The conflict stems from long-standing hostilities, particularly over Iran’s nuclear program, which Israel views as an existential threat. The situation has drawn international attention, with the United States distancing itself from Israel’s actions while maintaining strategic interests in the region.
The escalation has raised concerns about a wider regional war, with analysts warning of unintended consequences and further retaliation. The global markets have also reacted, with oil prices surging amid uncertainty.
Spy Prediction Potential breakout of bull flag if it bounces back after retest of 200 SMA. Could see an attempt for new ath.
Spy needs to reach 602.23 and hold that floor before the breakout. Watch for volume spike and close above 603. Watch for confirmation on the breakout.
Potential entries based on risk - 603.61 & 602.95
If volume or momentum declines, we could see a potential breakdown back towards 598.
Watch out for fakeouts.
GOLD poised for breakout GLD & /gcAfter going on a huge run to 317 we have spent a significant time now basing out and consolidating we’ve come down into that 300 range and tested and built up quite a bit of support
With the Iranian intentions we could kickstart the next move in gold 317 is the breakout. I am looking to play this breakout on an intra day pull back with some calls one month out for a swing Trey looking at the 320 or 325 strike price
SPY/QQQ Plan Your Trade For 6-13 : Harami-Inside PatternToday's pattern suggests the markets may stall into a sideways price range.
After the news of Israel targeting Iran in a preemptive strike late yesterday afternoon, the markets moved dramatically lower while Gold & Silver moved higher on the news.
I, personally, see this market trend as a shift in thinking ahead of a long Father's Day weekend.
I see traders trying to position their accounts/trades for uncertainty.
I believe we could see a bit of a shift today - particularly in Metals and the QQQ/NASDAQ/BTCUSD.
Overall, I strongly suggest traders prepare for extreme volatility this weekend as any further news of a counter-strike or further military action in the Middle East could roil the markets.
Happy Friday the 13th - everyone.
Going to be an interesting day to say the least.
Get some.
#trading #research #investing #tradingalgos #tradingsignals #cycles #fibonacci #elliotwave #modelingsystems #stocks #bitcoin #btcusd #cryptos #spy #gold #nq #investing #trading #spytrading #spymarket #tradingmarket #stockmarket #silver